Literature DB >> 14571617

[Effect of Panax notoginsenosides on the proliferation of hematopoietic progenitor cells in mice with immune-mediated aplastic anemia].

Yun Gai1, Rui-lan Gao, Yang-ping Niu.   

Abstract

OBJECTIVE: To study the effect of panax notoginsenosides (PNS) on the proliferation of hematopoietic progenitor cells (HPC) in mice with immune-mediated aplastic anemia.
METHODS: Balb/c mice model of immune-mediated aplastic anemia was established by radiation with sublethal dose of 60Co following the intravenously infusing lymphocytes of DBA/2 mice. Model mice in the treated groups were treated separately with high, middle and low dose of PNS, 3.2 mg, 1.6 mg and 0.8 mg per day respectively by intraperitoneal injection. Model mice in the control group and normal mice in the normal control group were treated with normal saline. The peripheral white blood cell (WBC) count and pathological examination of bone marrow were carried out 12 days later, the bone marrow was taken to be incubated in semi-solid culture system for observing proliferation of HPC.
RESULTS: PNS could (1) increase peripheral WBC count: as compared with that in the model control, WBC in the high, middle and low dose PNS groups was raised by (34.3 +/- 2.9)%, (29.2 +/- 1.7)% and (14.5 +/- 1.6)% respectively, P < 0.01 and P < 0.05; (2) improve the bone marrow inhibition: pathological examination showed in the model group, the hematopoietic structure was destroyed and replaced by fatty tissue, while in the PNS treated groups, the structure of marrow was rather complete and filled with abundant hematopoietic cells; (3) promote the proliferation of HPC: as compared with the model group, the colony formation of CFU-GM were increased by (64.4 +/- 2.8)%, (67.3 +/- 2.4)% and (21.9 +/- 1.8)% respectively and that of CFU-E increased by (31.9 +/- 3.6)%, (20.7 +/- 2.4)% and (12.8 +/- 2.6)% respectively in the three PNS treated group (P < 0.01 and P < 0.05).
CONCLUSION: PNS could enhance hematopoiesis by promoting proliferation of CFU-GM and CFU-E progenitors so as to improve the hematopoietic function in mice of immune-mediated aplastic anemia.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14571617

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  6 in total

1.  Research and development of new Chinese materia medica for treatment of refractory hematopathy by establishment and application of multiple technique platforms.

Authors:  Rui-lan Gao
Journal:  Chin J Integr Med       Date:  2007-06       Impact factor: 1.978

2.  Research and development of the effective components of panaxdiol saponin as new Chinese patent medicine for treating hemocytopenia.

Authors:  Rui-lan Gao; Beng Hock Chong
Journal:  Chin J Integr Med       Date:  2012-12-13       Impact factor: 1.978

3.  Effect of Fuzheng Yiliu decoction combined with chemotherapy on patients with intermediate and late stage gastrointestinal cancer.

Authors:  Bin Pan; Tao Cheng; Ke-Jun Nan; Gen-Quan Qiu; Xi-Cai Sun
Journal:  World J Gastroenterol       Date:  2005-01-21       Impact factor: 5.742

4.  Panax notoginseng saponins induced up-regulation, phosphorylation and binding activity of MEK, ERK, AKT, PI-3K protein kinases and GATA transcription factors in hematopoietic cells.

Authors:  Xin Sun; Rui-Lan Gao; Xiao-Jie Lin; Wei-Hong Xu; Xiao-Hong Chen
Journal:  Chin J Integr Med       Date:  2013-01-31       Impact factor: 1.978

5.  Effects of Panax notoginseng saponins on proliferation and differentiation in NIH3T3 cells.

Authors:  Li-Ming Yin; Xiao Wang; Xu-Dai Qian; Xiao-Jie Lin; Xiao-Hong Chen; Rui-Lan Gao
Journal:  Chin J Integr Med       Date:  2012-08-02       Impact factor: 1.978

6.  GPX3 methylation is associated with hematologic improvement in low-risk myelodysplastic syndrome patients treated with Pai-Neng-Da.

Authors:  Shujun Yang; Tong Gao; Zhonghua Zheng; Binbin Lai; Lixia Sheng; Zhijuan Xu; Xiao Yan; Jiaping Wang; Shiwei Duan; Guifang Ouyang
Journal:  J Int Med Res       Date:  2020-09       Impact factor: 1.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.